RCEL Stock Price & Analysis

Record Revenue Achievement: We exceeded our second quarter record revenue, surpassing it by 29%, achieving $19.5 million in commercial revenue during Q3.

Revenue Transition Success: By the end of September, we successfully transitioned approximately 75% of our revenue base to RECELL GO, demonstrating our operational agility.

Rapid FDA Approval Execution: We managed to do this within just four months of FDA approval, showcasing our execution capabilities.

Q4 Commercial Revenue Forecast: We expect commercial revenue to be in the range of $22.3 million to $24.3 million for Q4, representing sequential growth of 14% to 25% over the third quarter.

Gross Profit Margin Outlook: Gross profit margin for the quarter was 83.7%, with expectations to be in the range of 85% to 86% for the full year 2024.

Gross Profit Margin Decline: Gross profit margin for the quarter was 83.7%, down slightly from 84.5% in the same period of 2023.

Operating Expenses Increase: Total operating expenses for the quarter were $30.2 million, compared to $21.1 million in the same period in 2023.

Operating Expenses Increase: The increase in operating expenses is primarily attributable to an increase of $4.6 million in sales and marketing expenses due to employee-related costs.

Quarterly Net Loss Increase: Net loss for the third quarter was $16.2 million, or a loss of $0.62 per basic and diluted share, compared to a net loss of $8.7 million, or a loss of $0.34 per basic and diluted share in the same period in 2023.

Cash and Marketable Securities Decline: As of September 30th, we had cash, cash equivalents, and marketable securities of $44.4 million, compared to $89.1 million as of December 31, 2023.